A Brockton mother who says she had no idea she was pregnant ended up giving birth in an ambulance during a January blizzard, then spent the next five months shuttling to a Boston NICU before finally bringing her tiny son home. The baby, Julian, arrived at roughly 22 weeks and spent months on intensive support before his discharge at the end of June. Clinicians initially described his chances of survival as slim, and the family says the way he arrived and then pulled through has felt nothing short of a miracle.
How It Unfolded
According to ABC News, Alysha MacDougall woke in the early hours of Jan. 26, 2026, with severe stomach pains and bleeding, despite a string of negative pregnancy tests. Her fiancé, Carl Pina, called 911 and then followed the ambulance through a snowstorm as paramedics rushed her to care. MacDougall told reporters she had been diagnosed with polyendocrine metabolic ovarian syndrome and was taking a GLP‑1 medication for weight management, assuming that her nausea and other changes were side effects from the drug rather than signs of pregnancy. The couple said Julian ultimately spent about 154 days in the neonatal intensive care unit before coming home on June 29, 2026.
Why GLP‑1 Symptoms Can Be Confusing
Experts note that GLP‑1 receptor agonists often cause gastrointestinal side effects, including nausea, vomiting and appetite changes, symptoms that overlap with early pregnancy, according to Stanford Medicine. That overlap, combined with conditions such as PMOS (previously known as PCOS) that can change menstrual patterns or fertility, can make pregnancy harder to recognize, the Mayo Clinic notes. MacDougall said she took multiple home pregnancy tests that were negative and never expected that she would be in labor that night.
What the Data Show About Early Exposure
A recent large analysis led by researchers at the Harvard T.H. Chan School of Public Health found that GLP‑1 exposure during the first trimester “does not appear to substantially increase the risk of adverse outcomes,” including non‑live birth, major congenital malformations and abnormal fetal growth, the authors reported. The study, published in the Annals of Internal Medicine and summarized by Harvard’s communications team, relied on insurance‑claims data and highlighted that inadvertent early exposure has become more common in recent years. The paper’s corresponding author, Jeremy Brown, stressed that the findings do not answer questions about safety with continued use later in pregnancy.
What Doctors Recommend
Because human data remain limited and animal studies have suggested potential fetal harm, clinicians typically recommend that people planning a pregnancy stop GLP‑1 drugs before conceiving. Prescribing information for semaglutide‑brand products advises discontinuing the medication at least two months before a planned pregnancy. For decisions about stopping a drug or switching to another therapy, experts say patients should talk through timing and contraception with their clinicians and obstetric teams, and product labels and professional guidance both emphasize individualized counseling. These precautions are intended to cut down the risk of inadvertent exposure while more human safety data accumulate.
Parents and Clinicians React
At Tufts Medical Center, the neonatal team described Julian as “critically ill” when he arrived, and said he slowly stabilized with maximal NICU care that included specialized ventilation and round‑the‑clock support, ABC News reported. Dr. Jaclyn Boulais, the NICU medical director, said survival odds for infants born that early are low and called Julian’s discharge home a remarkable outcome. The parents thanked the NICU staff and said that bringing Julian home on June 29, 2026, closed a grueling chapter and marked the start of ordinary parenting worries.
Why This Matters Locally
The case has become a vivid reminder for reproductive‑age patients and local clinicians that the rapid rise in GLP‑1 prescriptions, both for diabetes and for weight management, is colliding with pregnancy planning and detection. Coverage of the family’s story by outlets including Cleveland.com has prompted renewed questions about how prescribers talk with patients about contraception and pregnancy testing when starting these medications. For now, doctors are urging clear, proactive conversations between prescribers and anyone of childbearing potential about risks, contraception and future plans for conception.
